Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese

被引:1
|
作者
Shang, Guoguo [1 ,2 ,3 ]
Jin, Yan [1 ,2 ]
Zheng, Qiang [1 ,2 ]
Shen, Xuxia [1 ,2 ]
Yang, Mu [4 ]
Li, Yuan [1 ,2 ]
Zhang, Lanjing [5 ,6 ,7 ,8 ]
机构
[1] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Pathol, Sch Med, Shanghai, Peoples R China
[5] Rutgers State Univ, Dept Biol Sci, Newark, NJ USA
[6] Med Ctr Princeton, Dept Pathol, Plainsboro, NJ USA
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[8] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Chem Biol, Piscataway, NJ USA
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2019年 / 9卷 / 06期
基金
中国国家自然科学基金;
关键词
Lung cancer; pathology; survival; oncogenic driver; adenocarcinoma; INVASIVE MUCINOUS ADENOCARCINOMA; CLINICOPATHOLOGICAL CHARACTERISTICS; INTERNATIONAL ASSOCIATION; FUSIONS DEFINE; RET FUSIONS; ALK; MUTATIONS; PROGNOSIS; SUBTYPES; SMOKERS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known about association of mucin abundancy with oncogenic-driver alterations, immunohistochemical and clinicopathologic features in lung adenocarcinomas among Chinese. We here retrospectively examined the clinicopathologic and molecular characteristics of pulmonary mucin-producing adenocarcinoma (PMPA) and previously-reported non-mucinous lung adenocarcinomas collected at our institution. Among the 897 non-mucinous adenocarcinomas, 61 PMPA with <= 90% mucin and 39 PMPA with >90% mucin, ALK rearrangements were found in 47 (5.2%) non-mucinous adenocarcinomas, 9 (14.8%) PMPA with 5.90% mucin and 12 (30.8%) PMPA with >90% mucin, respectively, with an ordinal association (coefficient, 95% CI=0.11, 0.06 to 0.17). Similarly, KRAS mutations was found in 53 (5.9%) non-mucinous adenocarcinomas, 7 (11.5%) PMPA with <= 90% mucin and 14 (35.9%) PMPA with >90% mucin (coefficient, 95% CI=0.11, 0.05 to 0.16). However, mucinous abundancy was inversely, ordinally linked to the EGFR mutations (coefficient, 95% C1=-0.28, -0.33 to -0.22). Mucin abundancy seemed not associated with the alterations of HER2, BRAF, ROS1, MET and RET. We divided PMPA with >90% mucin into three histologic types, namely columnar mucinous cell with basal nuclei (type I, n=11), cuboidal cell with goblet cell feature (type II, n=16) and mucinous cribriform pattern (type III, n=12). These histologic subtypes were associated with alterations of ALK, KRAS and MET, and the immunohistochemical reactivity of MUC1, MUC2, MUC5ac, MUC6, TTF-1 and CK20, including high positive rate of MUC6 (90.9%) and CK20 (36.4%) in type I, MUC2 (50%) in type II and MUC1 (100%) in type III. In summary, mucin abundancy is associated with immunohistochemical and oncogenic-driver profiles of lung adenocarcinomas among Chinese.
引用
收藏
页码:1212 / 1223
页数:12
相关论文
共 50 条
  • [1] Frequency of oncogenic alterations in five driver genes in Chinese female lung adenocarcinoma.
    Xu, Ren
    Ma, Jie
    Xie, Li-Qun
    Tao, Hui-Qing
    Wei, Bing
    Guo, Yong-Jun
    Bao, Wen-Jing
    Tong, Guang-Quan
    Ding, Lu
    Zhan, Min-Ning
    Yong, Ma Zhi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases
    Hu, Mingming
    Zhang, Tongmei
    Yang, Yuan
    Che, Nanying
    Li, Jie
    Liu, Zichen
    Li, Baolan
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2020, 35 (04): : 44 - 50
  • [3] Oncogenic ARAF as a new driver in lung adenocarcinoma.
    Araujo, Luiz H.
    Amann, Joseph
    Imielinski, Marcin
    Greulich, Heidi
    Meyerson, Matthew
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Oncogenic ARAF as a New Driver in Lung Adenocarcinoma Translational Research
    Araujo, L.
    Amann, J.
    Imielinski, M.
    Greulich, H.
    Meyerson, M.
    Carbone, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S73 - S73
  • [5] Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
    Tan, Aaron C.
    Tan, Daniel S. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 611 - +
  • [6] 5 DRIVER GENES IN CHINESE FEMALE LUNG ADENOCARCINOMA
    Han, Baohui
    Wei, Bing
    Dong, Yu
    Ma, Zhiyong
    Ma, Jie
    Tao, Huiqing
    Xiong, Hui
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1255 - S1255
  • [7] Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma
    Tanaka, Kosuke
    Hida, Toyoaki
    Oya, Yuko
    Yoshida, Tatsuya
    Shimizu, Junichi
    Mizuno, Tetsuya
    Kuroda, Hiroaki
    Sakakura, Noriaki
    Yoshimura, Kenichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Yatabe, Yasushi
    CANCER, 2017, 123 (10) : 1731 - 1740
  • [8] Oncogenic driver mutation analysis in lung adenocarcinoma: A single center study in India
    Kulkarni, S. S.
    Rauthan, A.
    Patil, P.
    Sood, T.
    Somashekhar, S.
    Zaveri, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma
    De Maio, Andrew
    Clarke, Jeffrey M.
    Dash, Rajesh
    Sebastian, Siby
    Wahidi, Momen M.
    Shofer, Scott L.
    Cheng, George Z.
    Li, Xuechan
    Wang, Xiaofei
    Mahmood, Kamran
    JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY, 2019, 26 (02) : 96 - 101
  • [10] Practical screening system of oncogenic driver fusions in lung adenocarcinoma, using the NanoString nCounter
    Takamochi, K.
    Suehara, Y.
    Takahashi, F.
    Mogushi, K.
    Kohsaka, S.
    Mano, H.
    Takeuchi, K.
    Saito, T.
    Hayashi, T.
    Takahashi, K.
    Suzuki, K.
    ANNALS OF ONCOLOGY, 2017, 28